Effect of Laggera alata on hepatocyte damage induced by carbon tetrachloride in vitro and in vivo.
BACKGROUND
Laggera alata, as a traditional Chinese herbal medicine, has been widely used to ameliorate some ailments associated with inflammation including hepatitis in folk.


OBJECTIVE
Based on anti-inflammatory activity of total phenolics from Laggera alata (TPLA), to further validate the remarkable curative effect Laggera alata in hepatitis, hepatoprotective effect of TPLA was examined.


METHODS
TPLA was prepared and its principle components were quantificationally analyzed. The hepatoprotective effects of TPLA were studied using a CCl(4)-induced injury model in primary cultured neonatal rat hepatocytes, and a CCl(4)-induced acute and chronic damage model in vivo.


RESULTS
TPLA significantly reduced cellular leakage of hepatocyte aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and improved cell viability in vitro. TPLA markedly decreased the serum AST and ALT levels of the mice, the levels of AST, ALT, total protein, albumin, and sialic acid in rat serum, and the hydroxyproline level in rat liver. Meanwhile, severe hepatic lesions induced by CCl(4) in mice/rats were remarkably improved by the administration of TPLA.


CONCLUSIONS
This investigation verifies the hepatoprotective effect of TPLA in vitro/in vivo and clarifies its active components dicaffeoylquinic acids responsible for hepatoprotective potential.
Wu
Yi-Hang
YH
Department of Pharmacy, College of Life Sciences, China Jiliang University, Xiasha Higher Education Zone, Hangzhou, China. yihangwu@126.com
Zhang
Xiao-Meng
XM
Hu
Ming-Hui
MH
Wu
Xiu-Mei
XM
Zhao
Yu
Y
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D019659:Asteraceae / Q000737:chemistry*; D001798:Blood Proteins / Q000187:drug effects; D002251:Carbon Tetrachloride; D002470:Cell Survival / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D006909:Hydroxyproline / Q000378:metabolism; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D019158:N-Acetylneuraminic Acid / Q000097:blood; D008517:Phytotherapy; D010936:Plant Extracts / Q000737:chemistry / Q000627:therapeutic use*; D011801:Quinic Acid / Q000031:analogs & derivatives*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012709:Serum Albumin / Q000187:drug effects
D001798:Blood Proteins; D004365:Drugs, Chinese Herbal; D010936:Plant Extracts; D012709:Serum Albumin; D011801:Quinic Acid; D002251:Carbon Tetrachloride; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D019158:N-Acetylneuraminic Acid; D006909:Hydroxyproline